The Mycoplasma
Testing Market report discusses the
primary market growth drivers and challenges that the vendors and the market as
a whole face and provides an overview of the key trends emerging in the market.
This study also shows about the industry size of different segments and their
growth aspects along with key leading countries in Americas, Asia-Pacific,
Europe, the Middle East, and Africa regions.
Industry insights
The global mycoplasma testing market was valued at USD 446.9 million in
2016 and is anticipated to witness a lucrative growth over the forecast period.
Rising number of pharmaceutical and biopharmaceutical companies, increasing
R&D investment, and growing number of drug launches are major attributes
that are fuelling the market.
Increase in the number of biopharmaceutical and pharmaceutical companies
has been seen in the past years. This growth has been attributed by the need
for advanced drugs and therapies for the treatment of chronic diseases like
cancer, diabetes, cardiovascular diseases and osteoporosis among others. The
research work is supported by the government by funding the pharmaceutical and
biotechnology companies in order to facilitate research based activities for
the development of new drugs. This may foster the growth of mycoplasma testing
market.
Download Free Sample Report Now @ https://www.millioninsights.com/industry-reports/mycoplasma-testing-market/request-sample
Main features of the report:
·
To provide detailed analysis of
the market structure along with forecast of the various segments and
sub-segments of the global Mycoplasma Testing Market.
·
A complete backdrop analysis,
which includes an assessment of the parent market
·
Important changes in market
dynamics
·
Market segmentation up to the
second or third level
·
To provide country level
analysis of the market for segment by application, product type and
sub-segments.
·
To provide strategic profiling
of key players in the market, comprehensively analyzing their core
competencies, and drawing a competitive landscape for the market.
·
Track and analyze competitive
developments such as joint ventures, strategic alliances, mergers and
acquisitions, new product developments, and research and developments in the
global Mycoplasma Testing Market.
·
Emerging niche segments and
regional markets
·
An objective assessment of the
trajectory of the industry.
Rising investment in R&D by dominant players has further resulted in
growth of the market. In the year 2016, North America spent 28.4% of its GDP on
research and development according to Global R&D Funding Forecast. This
signifies significant rise in the spending by various companies for the
invention of new and enhanced testing devices and kits. With the growing
expenditure by the government in the healthcare industry and awareness
campaigns have led to the growth of the mycoplasma testing market. Mycoplasma
testing is conducted so as to ensure the product is contamination free during
each stage of manufacturing process.
Mycoplasma contamination is a major cause of concern in research and
development activities. Infections caused by M. orale or M. fermentans are
strains that frequently are seen in humans are a key source of contamination in
laboratory settings. These contaminations in cell cultures cause morphological
changes, altered cell metabolism and chromosomal aberrations causing
contamination in the entire cell line. Contamination may also result in serious
complications such as pneumonia, genital infections and other respiratory
disorders is also seen. Thus, to prevent such contaminations, mycoplasma
testing is vital.
Technology Insights
On the basis of technology, PCR segment held the largest share in 2016.
PCR helps to detect the mycoplasma using its double stranded DNA. The DNA of
the mycoplasma are amplified, and then a dye is used which attaches to the DNA
and emits light. This shows the presence of mycoplasma.
Microbial culture is expected to show lucrative growth over the forecast
period. The increasing number of research activities in academics, research
laboratories, pharmaceutical and biopharmaceutical companies is supporting the
growth.
Application Insights
On the basis of application, cell line testing held the largest share in
2016. Cell line testing is generally conducted in the laboratory and is the
major source of mycoplasma contamination. This segment is expected to show
growth over the forecast period due to increasing application of mycoplasma
testing to avoid contamination in the cell culture.
End of production cells is projected to show lucrative growth over the
forecast period due to the increase in clinical trials for drug discovery and
development. The quality control taken in the drug discovery is majorly
contributing to the of this segment share.
End-use Insights
On the basis of end use, pharmaceutical and biotechnology companies
contributed towards the largest share in 2016. The government’s support along
with the huge investment made by these companies in the R&D activities has
led to the development new drugs which in turn has contributed to the growth of
the market.
Contract research organisations are projected to show attractive growth
over the forecast period because large number of research activities is
conducted by these organisations which are outsourced by the pharmaceutical and
biotechnology companies.
Regional Insights
North America dominated the market in 2016 owing to the rising
healthcare expenditure made by the US government in R&D activities for the
development of new drugs. There is also spending on healthcare infrastructure
which contributes to the growth.
Asia Pacific region is projected to show a lucrative growth over the
forecast period owing to increasing awareness and funding initiatives
undertaken by the government for the development of new drugs.
Competitive Insights
Some of the major key players of the market include Charles River
Laboratories International, Inc.; Merck KGaA; Lonza Group Ltd.; Thermo Fisher
Scientific; PromoCell GmbH; ATCC (American Type Culture Collection); Biological
Industries Israel Beit Haemek Ltd.; Bionique Testing Laboratories, Inc.; and
InvivoGen.
The leading manufacturers provide an extensive range of advanced testing
products through their strong distribution channels across wide geographical
locations. The significant strategies causing the growth of these companies
include new product development, geographical expansions, and mergers &
acquisitions. For example, in November 2015, Merck acquired Sigma-Aldrich Co.,
one of the major in the industry.
Know
More Insights @ https://newsonmarketblog.wordpress.com
No comments:
Post a Comment